Can platinum compounds and tungsten exposure impair mitochondrial function?

Oxidative stress and membrane damage

• Exposure to platinum-based compounds (such as cisplatin and oxaliplatin) and tungsten (such as sodium tungstate) triggers massive cellular generation of reactive oxygen species (ROS) while depleting critical endogenous antioxidant defenses, specifically glutathione (GSH).
• This induced oxidative stress drives lipid peroxidation—evidenced by the accumulation of malondialdehyde (MDA)—which directly degrades the structural integrity of the inner mitochondrial membrane and depletes cardiolipin.
• Elevated ROS and membrane damage trigger the opening of the mitochondrial permeability transition pore (MPTP), causing a rapid collapse of the mitochondrial membrane potential and initiating apoptotic signaling pathways.

Respiratory chain and enzyme disruption

• Platinum compounds directly target and inhibit mitochondrial respiratory complexes I–IV, with particularly severe impairment localized to Complex I and Complex IV, which abruptly halts oxygen consumption.
• Tungsten exposure, evaluated in organelle models at concentrations such as 2 mM sodium tungstate, acts as a global respiratory chain inhibitor that destabilizes mitochondrial bioenergetics.
• The disruption of these respiratory complexes forces electrons to leak from the transport chain, creating a self-amplifying cycle of additional ROS generation, loss of oxidative phosphorylation, and acute ATP depletion.

Bottom line

• Both platinum compounds and tungsten exposure cause severe mitochondrial impairment through a dual-action mechanism: they generate overwhelming oxidative stress that compromises membrane integrity and directly disrupt critical electron transport chain complexes (specifically Complexes I and IV), culminating in bioenergetic failure.